First own Gerresheimer Autoinjector

From Midas Pharma, Gerresheimer acquired the IP for a new generation of cartridge-based autoinjectors. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector. Midas Pharma and Gerresheimer are combining their complementary strengths to market auto-injectors that combine the capabilities of both companies – Gerresheimer as a provider of medical products and primary packaging solutions and Midas Pharma as an experienced facilitator and provider of products and services along the pharmaceutical value chain.

With the partnership with Midas Pharma, we are moving towards becoming a leading provider of medical devices that are innovative and leading-edge. Dietmar Siemssen, CEO of Gerresheimer AG, said, “With an increasing focus on own-IP products, we complement the wide range of devices and pharmaceutical primary packaging we already have.”. We view this as the beginning of a successful collaboration with Midas Pharma and their expertise as a pharmaceutical service provider.”